These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 8891470

  • 21. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML.
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [Abstract] [Full Text] [Related]

  • 22. CPT-11: the European clinical development.
    Terret C, Couteau C, Armand JP.
    J Infus Chemother; 1996 Oct; 6(3):152-7. PubMed ID: 9229329
    [Abstract] [Full Text] [Related]

  • 23. Benefit-risk assessment of irinotecan in advanced colorectal cancer.
    Glimelius B.
    Drug Saf; 2005 Oct; 28(5):417-33. PubMed ID: 15853443
    [Abstract] [Full Text] [Related]

  • 24. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD.
    Cancer; 1999 Feb 15; 85(4):786-95. PubMed ID: 10091755
    [Abstract] [Full Text] [Related]

  • 25. CPT-11. The European experience.
    Armand JP, Terret C, Couteau C, Rixe O.
    Ann N Y Acad Sci; 1996 Dec 13; 803():282-91. PubMed ID: 8993522
    [Abstract] [Full Text] [Related]

  • 26. [Irinotecan in combination for colon cancer].
    Ducreux M, Gil-Delgado M, André T, Ychou M, de Gramond A, Khayat D.
    Bull Cancer; 1998 Dec 13; Spec No():43-6. PubMed ID: 9932084
    [Abstract] [Full Text] [Related]

  • 27. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E, Blijham GH.
    Semin Oncol; 1999 Feb 13; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [Abstract] [Full Text] [Related]

  • 28. [Standard therapy of CPT-11 for colorectal cancer].
    Saitoh S, Sakata Y.
    Gan To Kagaku Ryoho; 2001 Oct 13; 28(10):1345-51. PubMed ID: 11681240
    [Abstract] [Full Text] [Related]

  • 29. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M.
    J Clin Oncol; 1997 Jan 13; 15(1):251-60. PubMed ID: 8996150
    [Abstract] [Full Text] [Related]

  • 30. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V.
    Br J Cancer; 2000 Aug 13; 83(4):431-7. PubMed ID: 10945486
    [Abstract] [Full Text] [Related]

  • 31. Clinical pharmacokinetics of irinotecan.
    Chabot GG.
    Clin Pharmacokinet; 1997 Oct 13; 33(4):245-59. PubMed ID: 9342501
    [Abstract] [Full Text] [Related]

  • 32. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
    Cunningham D.
    Eur J Cancer; 1996 Oct 13; 32A Suppl 3():S1-8. PubMed ID: 8943658
    [Abstract] [Full Text] [Related]

  • 33. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.
    Oostendorp LJ, Stalmeier PF, Pasker-de Jong PC, Van der Graaf WT, Ottevanger PB.
    Anticancer Drugs; 2010 Sep 13; 21(8):749-58. PubMed ID: 20616701
    [Abstract] [Full Text] [Related]

  • 34. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, Dimitrakopoulos A, Karadima D, Rokana S, Papalambros E, Papastratis G, Margaris H, Tsipras H, Polyzos A.
    Cancer Chemother Pharmacol; 2003 Dec 13; 52(6):514-9. PubMed ID: 14504920
    [Abstract] [Full Text] [Related]

  • 35. The role of irinotecan in colorectal cancer.
    Saltz LB.
    Curr Oncol Rep; 1999 Dec 13; 1(2):155-60. PubMed ID: 11122813
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.